Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Deferred Revenue: 2015-2025

Historic Current Deferred Revenue for Adma Biologics (ADMA) over the last 8 years, with Jun 2025 value amounting to $143,000.

  • Adma Biologics' Current Deferred Revenue fell 87.35% to $143,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $143,000, marking a year-over-year decrease of 87.35%. This contributed to the annual value of $143,000 for FY2024, which is 21.43% down from last year.
  • Latest data reveals that Adma Biologics reported Current Deferred Revenue of $143,000 as of Q2 2025, which was down 0.00% from $143,000 recorded in Q1 2025.
  • In the past 5 years, Adma Biologics' Current Deferred Revenue registered a high of $1.1 million during Q2 2024, and its lowest value of $142,834 during Q1 2021.
  • Moreover, its 3-year median value for Current Deferred Revenue was $143,000 (2025), whereas its average is $343,050.
  • In the last 5 years, Adma Biologics' Current Deferred Revenue spiked by 691.13% in 2024 and then slumped by 87.35% in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' Current Deferred Revenue stood at $142,834 in 2021, then climbed by 0.12% to $143,000 in 2022, then grew by 27.27% to $182,000 in 2023, then declined by 21.43% to $143,000 in 2024, then slumped by 87.35% to $143,000 in 2025.
  • Its Current Deferred Revenue was $143,000 in Q2 2025, compared to $143,000 in Q1 2025 and $143,000 in Q4 2024.